MARKET

SGMO

SGMO

Sangamo Therapeutics Inc
NASDAQ
0.2469
-0.0604
-19.66%
Pre Market: 0.2550 +0.0081 +3.28% 06:18 04/01 EDT
OPEN
0.2350
PREV CLOSE
0.3073
HIGH
0.2487
LOW
0.2050
VOLUME
16.78K
TURNOVER
--
52 WEEK HIGH
0.8400
52 WEEK LOW
0.2050
MARKET CAP
102.28M
P/E (TTM)
-0.5628
1D
5D
1M
3M
1Y
5Y
1D
Sangamo Therapeutics Faces Rising Trade Policy Risks, Higher Costs and Global Growth Uncertainty
TipRanks · 4h ago
Sangamo Biosciences Balances Fabry Progress With Cash Risk
TipRanks · 10h ago
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 17h ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Terns Pharmaceuticals (TERN), Sangamo Therapeutics (SGMO) and Galectin Therapeutics (GALT)
TipRanks · 18h ago
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 22h ago
Why Virgin Galactic Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket
Benzinga · 1d ago
Sangamo targets summer 2026 for Fabry BLA submission while advancing neurology pipeline and partner talks
Seeking Alpha · 1d ago
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 1d ago
More
About SGMO
Sangamo Therapeutics, Inc. is a genomic medicine company. The Company’s zinc finger (ZF) epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid engineering platform has demonstrated the ability to expand delivery beyond available intrathecal delivery capsids, including in the central nervous system (CNS), in preclinical studies. Zinc finger technologies are derived from naturally occurring human proteins. They are composed of a DNA-binding domain, which binds with precision to any sequence of DNA, and various functional domains (such as nucleases and transcription factors) based on therapeutic needs. Its pipeline includes Chronic Neuropathic Pain - ST-503 and Isaralgagene civaparvovec (ST-920). ST-503 is an investigational epigenetic regulator for the treatment of intractable pain due to iSFN, a type of chronic neuropathic pain. ST-920 is a wholly owned gene therapy product candidate for the treatment of Fabry disease.

Webull offers Sangamo Therapeutics Inc stock information, including NASDAQ: SGMO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SGMO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SGMO stock methods without spending real money on the virtual paper trading platform.